Lorazepam has which notable safety consideration?

• A. Respiratory depression is not a concern
• B. It has no respiratory effects
• C. Respiratory depression risk especially for those with COPD and CO2 retention
• D. It improves respiratory function

Answer: (C)

The main safety point is that lorazepam can depress respiration, and this risk is especially important in people with COPD and chronic CO2 retention. Benzodiazepines like lorazepam enhance GABA activity in the brain, producing sedation and relaxation, but they also slow the brain’s control of breathing. In COPD with CO2 retention, patients already rely more on hypoxic drive and have limited ventilatory reserve; adding a CNS depressant can blunt the respiratory response to low oxygen or high carbon dioxide, increasing the chances of hypoventilation, hypoxemia, and even respiratory failure. For this reason, clinicians use the lowest effective dose, monitor breathing, avoid combining with other sedatives or opioids, and carefully assess respiratory status before giving this medication. It isn’t correct to say it has no respiratory effects or that it improves respiration—the depressant effect on the breathing center is real and clinically important, especially in those with COPD and CO2 retention.